AOD9604: A Lipolytic Fragment of Human Growth Hormone with Reduced Diabetogenic Activity
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM
Endocrinology · Vol. 142(12) · pp. 5182–5189 · 2001
Characterization of AOD-9604 as a selective lipolytic fragment of human growth hormone that stimulates fat breakdown without the diabetogenic effects of full HGH. Demonstrates targeted fat metabolism via beta-3 adrenergic receptor activation with a favorable safety profile.
Key Findings
AOD-9604 stimulates lipolysis in adipose tissue via beta-3 adrenergic receptor activation
Reduces body fat in obese animal models without affecting blood glucose or insulin
Does not activate IGF-1 pathways — avoids growth-promoting and diabetogenic effects of HGH
Oral bioavailability demonstrated — effective via oral and injectable routes
FDA GRAS (Generally Recognized As Safe) status obtained for food use
Methodology
In vitro adipocyte lipolysis assays combined with in vivo obese mouse and rat models. Metabolic profiling including glucose tolerance, insulin sensitivity, and body composition.
Limitations
Animal model data; human clinical trials showed modest effects in Phase 2/3 trials. Oral bioavailability in humans lower than in animal models.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment